PLAINSBORO, N.J., Mar 21, 2006 (PRIMEZONE via COMTEX News Network) -- Integra LifeSciences Holdings Corporation (Nasdaq:IART) today announced the release of the B-BOP® Basal Osteotomy Plating System, a unique fixation solution for hallux-valgus correction. The B-BOP Plating System has received clearance from the Food and Drug Administration (FDA) in the United States and a CE Mark Certification in the European Union. Integra will be highlighting the product at the American College of Foot and Ankle Surgeons annual meeting in Las Vegas this week.

The B-BOP® Plating System is the first system designed for plantar placement on the first metatarsal to stabilize osteotomies performed to correct moderate to severe hallux-valgus and hallux-varus. The system includes a plate that is placed on the tension side of the osteotomy to achieve greater stability.

The B-BOP Plate is manufactured from titanium alloy and is available in two versions for moderate and severe corrections. Additional product features include: an anatomic shape matching the plantar curve of the first metatarsal, color coding for easy size identification, and a low profile screw and plate design. Dedicated instrumentation aids in the assessment of the osteotomy site and the placement of the plate and screws.

"The B-BOP® Basal Osteotomy Plating System is another example of Newdeal products specifically designed by foot and ankle surgeons to address their unique needs in orthopedic surgery," said Gerard Carlozzi, Chief Operating Officer of Integra LifeSciences. "We are excited to launch this product in both Europe and the United States and to continue to add innovative products for our Reconstructive Surgery sales force."

The B-BOP Plating System will be sold by the Integra Reconstructive Surgery sales organization. Integra Reconstructive Surgery provides devices for the correction and reconstruction of the foot and ankle as well as wound care products and peripheral nerve repair products. Integra Reconstructive Surgery's direct selling effort in the United States currently includes more than 50 professionals.

Integra LifeSciences Holdings Corporation is a diversified medical technology company. Integra develops, manufactures, and markets medical devices used in a variety of applications. The primary applications for our products are neurosurgery, reconstructive surgery and general surgery. Integra is a leader in applying the principles of biotechnology to medical devices that improve patients' quality of life. Our corporate headquarters are in Plainsboro, New Jersey, and we have research, manufacturing and distribution facilities located throughout the world. We have approximately 1,400 employees. Please visit our website at http://www.Integra-LS.com.

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements concerning the use of the B-BOP Plating System. Such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from predicted or expected results. Among other things, the willingness of physicians to use the B-BOP Plating System may affect the prospects for its use in clinical procedures. In addition, the economic, competitive, governmental, technological and other factors identified under the heading "Factors That May Affect Our Future Performance" included in the Business section of Integra's Annual Report on Form 10-K for the year ended December 31, 2005 and information contained in subsequent filings with the Securities and Exchange Commission could affect actual results.

This news release was distributed by PrimeZone, www.primezone.com

SOURCE: Integra LifeSciences Holdings Corp.

Integra LifeSciences Holdings Corporation
John B. Henneman, III, Executive Vice President
Chief Administrative Officer
(609) 936-2481
jhenneman@Integra-LS.com

Maria Platsis, Senior Director of Corporate Development and Investor Relations
(609) 936-2333
mplatsis@Integra-LS.com